Semaglutide vs Retatrutide: Research Comparison
A Side-By-Side Research Comparison Of Semaglutide And Retatrutide - a GLP-1 agonist versus a triple-agonist incretin in metabolic research. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Semaglutide | Retatrutide | |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Compound Class | GLP-1 receptor agonist; fatty-acid conjugated 31-amino-acid peptide analog of human GLP-1 | Synthetic triple agonist: GIP receptor + GLP-1 receptor + glucagon receptor |
| Evidence Tier | Approved Drug | Investigational |
| Molecular Target | GLP-1 receptor (GLP1R); cAMP/PKA signaling; pancreatic beta-cell insulin secretion; hypothalamic appetite suppression; gastric emptying delay | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor) + GCGR (glucagon receptor); triple incretin/glucagon signaling for maximal metabolic effect |
| Molecular Weight | 4113.58 Da | 4731.3 Da |
| Amino Acid Sequence | 31-aa GLP-1 analog (Aib2, C18 diacid) | 39-aa GIP/GLP-1/glucagon tri-agonist (acylated) |
| CAS Number | 910463-68-2 | 2381089-83-2 |
| Half-Life | ~1 week | ~1 week |
| Studied For | Type 2 diabetes management, Chronic weight management / obesity, Cardiovascular risk reduction, HbA1c lowering | Obesity / overweight, Type 2 diabetes, Liver fat / MASLD / NAFLD, Triple agonist weight loss |
About Semaglutide
The approved GLP-1 weight-loss and diabetes drug; compounded versions carry FDA cautions.
Read The Full Semaglutide MonographAbout Retatrutide
An investigational triple-agonist weight-loss peptide with strong early trial results.
Read The Full Retatrutide MonographKey Differences
- Evidence tier differs: Semaglutide is classified as Approved Drug; Retatrutide is classified as Investigational.
- Primary molecular target differs: Semaglutide acts on GLP-1 receptor (GLP1R); cAMP/PKA signaling; pancreatic beta-cell insulin secretion; hypothalamic appetite suppression; gastric emptying delay; Retatrutide acts on GIPR (GIP receptor) + GLP-1R (GLP-1 receptor) + GCGR (glucagon receptor); triple incretin/glucagon signaling for maximal metabolic effect.
Continue Researching
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.